Allison DeLaurentis

Allison DeLaurentis is a partner in the Life Sciences group at Goodwin. Allison has deep expertise representing pharmaceutical companies, medical device manufacturers, healthcare providers, and individuals in federal criminal, civil, and state attorneys general investigations and enforcement actions. Her expertise includes defending life sciences companies and healthcare companies in investigations and litigation involving fraud and abuse – particularly the Anti-Kickback Statute, False Claims Act Foreign Corrupt Practices Act, and Stark Law.

Allison also advises health care industry clients on compliance with federal and state regulations. She counsels clients on mitigating risks and implementing compliance programs. Allison joined Goodwin in 2023.

Representative matters include:

• Represented publicly traded medical device manufacturer in AKS investigation, resulting in a declination*
• Represented global pharmaceutical manufacturer in industry-wide investigation alleging AKS violations stemming from donations to charitable patient copay assistance foundations*
• Conducted internal investigation on behalf of a portfolio company pharmacy chain related to compliance with provider agreements and the AKS*
• Represented healthcare providers in enforcement actions alleging False Claims Act violations from improper billing and coding, medical necessity, and quality of care*
• Defended diagnostic testing laboratory in DOJ investigation involving allegations of FCA violations stemming from the ordering of medically unnecessary diagnostic tests*
• Represented Finance and Marketing executives and compliance officer in DOJ and SEC investigation alleging violations of the FCPA*
• Advised multinational, publicly traded pharmaceutical and medical device manufacturers on FCPA compliance*
• Represented several executives and employees of multiple publicly traded pharmaceutical companies in criminal and civil DOJ investigations alleging violations of the AKS, FCA, and HIPAA*
• Defended physician advisory and compliance company in FCA investigation related to admission status and denials management services, resulting in a declination*
• Represented global pharmaceutical manufacturer in FCA investigation alleging off-label promotion*
• Conducted internal investigations for multiple publicly traded companies related to conflicts of interest, accounting practices, AKS compliance, and misappropriation of trade secrets*
• Defended multinational supply chain logistics defense contractor in criminal investigation alleging violations of the Major Fraud Act*

* Denotes experience prior to joining Goodwin.

Allison was selected to the Benchmark Litigation: 40 & Under Hot List, Health Sciences Litigation, Philadelphia in 2021, 2022, and 2023.

• Co-Author, “Greenfield Fraught with Problems”: District of Massachusetts Holds But-For Causation Required in False Claims Act Cases Based on Kickbacks,” Goodwin Client Alert, October 5, 2023
• Co-Author, “The Supreme Court Holds that the False Claims Act’s Scienter Element Turns on Defendant’s Subjective Beliefs, Rejecting Seventh Circuit’s Objective Standard,” Goodwin Client Alert, June 5, 2023
• Co-Author, “DOJ Revises Corporate Compliance Guidance to Take on Compensation Incentives and Communications Preservation — With a Continued Emphasis on Individual Accountability,” Goodwin Client Alert, March 8, 2023
• Co-Author, “DOJ Announces Nationwide Voluntary Corporate Self-Disclosure Policy in Effort to Standardize and Incentivize Timely Self-Reporting,” Goodwin Client Alert, February 28, 2023
• Co-Author, “OIG: Continuing Education Programs Have Independent Value Under AKS,” Troutman Pepper, July 18, 2022
• Co-Author, “The 2021 Anti-Kickback Statute Year in Review and 2022 Outlook: What’s Old Is New,” Pratt’s Government Contracting Law Report, May 2022
• Co-Author, “2022 Updates to the AdvaMed Code: What You Need to Know,” Troutman Pepper, March 23, 2022
• Co-Author, “DOJ’s Case Against Ericsson Reinforces the Importance of Self-Disclosure for Companies Subject to DPAs and Monitorships,” Troutman Pepper, March 10, 2022
• Co-Author, “The 2021 Anti-Kickback Statute Year in Review and 2022 Outlook: What’s Old Is New,” Pratt’s Government Contracting Law Report, February 28, 2022
• Co-Author, “DOJ Announces Major Changes to Its Corporate Enforcement Policies,” Troutman Pepper, November 2, 2021
• Co-Author, “The AKS “Means What It Says” — But Some Manufacturers and Patients Are Still Between a Rock and a Hard Place on Copay Assistance,” Troutman Pepper, October 11, 2021
• Co-Author, “The Case for Early-Stage Compliance,” The ABA/CJS White Collar Crime Committee Newsletter, Winter/Spring 2022
• Speaker, “Webinar: Rethinking BYOD Policies and Device Management after DOJ Revisions to Corporate Criminal Enforcement Policies,” Troutman Pepper, December 15, 2022
• Panelist, “Key Strategies for Navigating Your Career,” Association of Corporate Counsel (ACC) Greater Philadelphia Chapter - Women’s Summit, November 16, 2022
• Speaker, “New DOJ Guidance Tightens Corporate Enforcement Strategy,” Troutman Pepper Podcast, September 27, 2022
• Speaker, “Anti-Kickback Statute Enforcement Year in Review and Outlook for 2021,” Troutman Pepper, March 25, 2021
• Quoted, “Telehealth, Electronic Records Draw Anti-Kickback Attention,” Bloomberg Law, February 25, 2021
• Quoted, “2 Former Leaders Charged in COVID-19 Outbreak at Holyoke Soldiers’ Home That Left 76 Dead,” Boston Globe, September 25, 2020